Alumis Inc.
ALMS
Rangering i aksjer
#10425
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Aksjekurs
$6.15
Sist synkronisert: 2026-10-16
Markedsverdi
$795.38M
Endring (1 dag)
-2.61%
Endring (1 år)
170.70%
Land
US
Handel Alumis Inc. (ALMS)
Kategori
Healthcare
Markedsverdi av Alumis Inc.(ALMS)
Markedsverdi: $795.38M
Per October 2026 har Alumis Inc. en markedsverdi på $795.38M. Dette gjør Alumis Inc. til det 10425th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Alumis Inc. fra 2023 til 2026
ALMS sammenlignet med topp 5 mest populære stocks
